Silence Therapeutics PLC - novel RNA therapeutics developer with offices in London and Berlin - Investment firm Frazier Life Sciences Public Fund purchases a 3% shareholding in the company for USD20 million.
"Frazier has a track record of partnering with science-driven healthcare businesses, and we are very pleased to welcome them as an important new shareholder in Silence. This comes at an exciting time for the Company as we progress two important, wholly owned clinical stage programs and rapidly expand our pre-clinical pipeline leveraging our mRNAi GOLD platform," says Chief Executive Officer Mark Rothera.
Current stock price: 555.00 pence, up 3.7% on Friday
Year-to-date change: up 8.0%
By Dayo Laniyan; dayolaniyan@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
